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The -463G/A and -129G/A myeloperoxidase-encoding gene 
polymorphism in chronic obstructive pulmonary disease 
Abstract
Introduction: Neutrophils are involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). Myeloperoxidase 
is an important bactericidal granulocytic enzyme. It is of interest to question whether or not the polymorphic variants of the 
myeloperoxidase-encoding gene are associated with the risk of developing COPD. 
Material and methods: The study determined the risk of COPD development in 186 COPD patients and 220 healthy subjects in 
the context of two selected polymorphic sites of the promoter region of the myeloperoxidase-encoding gene. 
Results: It has been demonstrated that the AA genotype of locus -463 in the myeloperoxidase-encoding gene increases the risk 
of developing COPD (OR: 2.87; CI: 1.651–4.997). This genotype also correlates with a higher gene expression in patients (0.56 
± 0.12 vs 0.31 ± 0.18 in patients with AG genotype and 0.29 ± 0.17, p < 0.01 in those with GG genotype). In healthy indivi-
duals, the AA genotype was also characterized by increased expression of the myeloperoxidase-encoding gene (0.41 ± 0.16 
vs 0.29 ± 0.15 for AG genotype, p < 0.01 and 0.25 ± 0.16 for GG genotype p < 0.01). Patients with the AA genotype had 
a significantly higher gene expression than healthy subjects with this genotype. 
Conclusions: The polymorphic site -129 of the myeloperoxidase-encoding gene was unrelated to the development of COPD. The 
gene expression did not differ for the individual genotypes. Our studies indicate that the polymorphism of the myeloperoxidase-
-encoding gene may be related to chronic obstructive pulmonary disease. 
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Introduction
Chronic obstructive pulmonary disease 
(COPD) inflammatory disease of the respiratory 
system which leads to irreversible airway obstruc-
tion and the formation of emphysematous bullae 
[1]. The neutrophil is one of the important cells 
involved in airway inflammation in COPD [2]. 
Neutrophils are phagocytes which secrete nume-
rous inflammatory mediators, including reactive 
oxygen species [3]. An enzyme important for the 
antimicrobial defense of neutrophils is myelope-
roxidase (EC 1.11.1.7) [4, 5]. This enzyme belon-
gs to the group of hemoproteins catalyzing the 
formation of hydrogen peroxide, chloride anions 
of toxic hypochlorites and, in lesser amounts, 
of tyrosine and nitrotyrosine radicals, singlet 
oxygen and ozone [4–6]. The above products kill 
bacteria and pathogenic fungi and cause damage 
to the genetic apparatus of some viruses such as 
HIV-1 [5]. The products of catalytic activity of 
myeloperoxidase also damage the host’s tissue 
[5]. An unfavorable contribution of this enzyme’s 
activity to the pathogenesis of many inflammatory 
diseases has been noted. These diseases include 
chronic obstructive pulmonary disease, ARDS, 
Alzheimer’s disease, multiple sclerosis, myocar-
dial infarction, stroke and many others [5]. 
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Myeloperoxidase (MPO) is encoded by the 
gene localized in the 17q23.1. fragment of chro-
mosome 17 in the cluster coding for numerous 
growth hormones [7]. Myeloperoxidase is one 
member of a gene family of mammalian peroxi-
dases that also includes eosinophil peroxidase, 
lactoperoxidase, thyroid peroxidase, and pro-
staglandin H synthase [7]. The mature enzyme 
is a 140-kDa dimer of identical halves, each 
containing two polypeptide chains of 108 and 
466 amino acids resulting from post-translational 
excision of 6 amino acids from a single poly-
peptide precursor. Each half-molecule contains 
a covalently bound heme that exhibits unusual 
spectral properties [7]. The significance of poly-
morphism of the myeloperoxidase-encoding 
gene in numerous human diseases has been 
demonstrated. Among others, the myeloperoxi-
dase gene polymorphism plays a role in the risk 
of gastric cancer [8], preeclampsia [9], lung and 
prostate cancer [10], coronary heart disease [11], 
periodontitis [12], chronic lymphocytic leukemia 
and multiple myeloma [13], as well as in many 
other pathologies. In our own studies, we have 
not demonstrated the correlation of the myelo-
peroxidase gene polymorphism with macular 
degeneration [14]. 
Research and discussion of whether polymor-
phism of the gene coding for myeloperoxidase 
plays a role in the pathogenesis of COPD is war-
ranted. Neutrophils and mediators produced by 
them are one of the main pathogenic pathways of 
this disease [15]. On the one hand, myeloperoxi-
dase is an enzyme of the antimicrobial defense 
system but on the other, its harmful effect on the 
tissue has been demonstrated [16–18]. 
The purpose of this study was to evaluate the 
frequency of alleles and two polymorphic sites of 
the myeloperoxidase-encoding gene.
Material and methods
In our study, we examined 186 patients with 
COPD and 220 healthy controls. There were no 
statistical differences in sex and age between the 
groups of patients and the healthy controls. The 
study exclusion criteria for the patients were as 
follows: a history of malignant tumors, collageno-
sis and systemic vasculitis, type 2 diabetes mel-
litus, bronchial asthma, and asthma and COPD 
overlap. All of the subjects forming the study 
group and the control group were smokers or ex-
-smokers with a minimum number of 10 smoking 
pack-years. The age of the participants ranged 
from 45 to 70 years. The group of patients with 
COPD included 50 at risk level A, 56 at level B, 
34 at risk C, and 46 at risk level D. The allele 
frequency distribution was not analyzed with 
respect to the level of COPD risk because of an 
insufficient size of the groups. 
In the group of 186 patients, the mean age 
was 62 years of age with a standard deviation 
of 7 years, and in the control group the mean 
age was 60 with a standard deviation of 9. The 
differences were not statistically significant. 
The youngest patient was 48 years old while the 
youngest healthy subject was 45 years old. Among 
186 patients, 56 were women and 130 were men. 
The control group consisted of 66 women and 
154 men. Gender distribution did not differ be-
tween the two groups. 
Reagents
All reagents used were of analytical grade. 
The restriction enzymes as well as Taq DNA poly-
merase were procured from Promega (Madison, 
WI, USA). Oligonucleotides were synthesized at 
IDT (Coralville, IA, USA). 
DNA extraction 
Blood DNA was purified on a QIAamp spin 
column (Qiagen, Hilden, Germany) using the pro-
tocol for DNA isolation from body fluids provided 
by the manufacturer and modified as follows: 
5 μg of RNA poly(A) (Pharmacia Biotech, Uppsala, 
Sweden) was added to 1 mL of serum to serve as 
a carrier to improve the recovery of small amo-
unts of DNA. Lysis was ensured by adding 20 μL 
of Qiagen Proteinase K solution and 1 mL of AL 
buffer (QIAamp® DNA mini kit). After 10-min of 
incubation at 56°C, 1 mL of ethanol was added. 
The mixture was loaded on the QIAamp spin 
column and centrifuged at 20000 g for 1 min. 
The column was washed twice by adding 500 μL 
of AW buffer (QIAamp® DNA mini kit) and cen-
trifuged at 20000 g for 1 min. Finally, DNA was 
incubated for 5 min at room temperature with 
50 μl of AE buffer and eluted by centrifugation. 
Polymorphism of MPO gene (-463, -129)
The isolated DNA was used for amplification 
of -463 and -129 SNP sequences of MPO human 
gene. The PCR reactions and conditions were 
identical for both polymorphisms by applying 
starters: 5’CGGTATAGGCACACAATGGTGA 3’, 
5’GCAATGGTTCAAGCGATTCTTC 3’ specific for 
-463 polymorphism and 5’TGGGCAACAGAGCA-
AGATAA3’, 5’CTCTTT CTCCTCCCCCACTG3’ 
specific for -129. Amplification was performed 
in a total volume of 25 μL containing 50ng of 
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DNA, 50 pM PCR primers, dNTP, each at a con-
centration of 80 μM and 1U of GoTaq polymerase 
(Promega). PCR conditions were as follows: 94°C 
for 30 sec, 59°C for 30 sec and 72°C for 30 sec 
(35 cycles). The final elongation step was 10 min 
at 72°C. The amplification products of 350 bp 
length (-463 polymorphism) were digested with 
AciI restriction enzyme at 37°C and separated 
on 3% agarose gel. The digestion of homozygote 
GG yields three fragments of 169 bp, 120 bp and 
61 bp, heterozygote GA 289 bp, 169 bp, 120 bp 
and 61 bp fragments and homozygote AA 289 bp, 
61 bp fragment. The genotyping of the -129 SNP 
sequences of the MPO human gene was analyzed 
by directly sequencing the PCR product. Amplifi-
cation was performed under the same conditions 
using 0.1 μg genomic DNA, 200 μM each dNTP, 
5 × GoTaq buffer solution, 1U GoTaq polymerase 
(Promega, Madison WI USA), 0.5 μM primers. 
Amplification of the product of 129 bp was sequ-
enced using a specific primer labelled with biotin 
molecule 5’ATTTCAGG ’3’ by DNA sequencing 
service IBB PAN (Warsaw Poland). 
RNA purification and real time RT-PCR 
The human myeloperoxidase and GADPH 
gene expression was quantified by real-time 
PCR using ABI Prism 7000 Sequence Detection 
System (Applied Biosystems, Foster City, CA 
USA) according to the manufacturer’s protocol. 
Total cellular RNAs were extracted from the pa-
tients’ whole blood cells using the Trizol reagent 
(Invitrogen, Groningen, Nederlands) method, 
a single-step purification protocol [19]. Polyade-
nylated RNA was isolated using an Oligotex kit 
(Qiagen, Chatsworth, CA USA). 50 ng of poly(A) 
RNA was then used for cDNA synthesis using the 
TaqMan Reverse Transcription Reagents kit (Ap-
plied Biosystem) according to the manufacturer’s 
protocol. Briefly 2.5, 2.0; 1.5, 1.0; 0.5 and 0.25 μL 
of synthesized cDNA were amplified in triplicate 
for both GADPH and each of the target genes to 
create a standard curve. Likewise, 2 μl of cDNA 
was amplified in triplicate in all isolated samples 
for each primer/probe combination and GADPH. 
Each sample was supplemented with both re-
spective 0.3 μM forward and reverse primers, 
fluorescent probe, and made up to 50 μL using 
qPCRTMMastermix for SYBIR Green I (Eurogentec 
Seraing Belgium). All following PCR primers 
were designed using  software PrimerExpress 
(Applied Biosystem) forward 5’CCACCAAAAC-
CGATCACCAT 3’, reverse 5’CACTCCTCGCCTG 
CATCAT 3’forward, 5’AGCCACATCGCTCAGA-
CAC 3’, reverse 5’ GCCCAATACGAC CAAATCC 
3’ specific for mRNA of human myeloperoxidase 
and GADPH respectively. GADPH was used as 
an active and endogenous reference to correct 
for differences in the amount of total RNA added 
to the reaction and to compensate for different 
levels of inhibition during reverse transcription 
of RNA and during PCR. Each target probe was 
amplified in separate 96-well plate. All samples 
were incubated at 50°C for 2 min. and at 95°C 
for 10 min. and then cycled at 95°C for 30 sec, 
56°C for 1 min. and 72°C for 1 min. for 40 cycles. 
SYBR Green I fluorescence emission data were 
captured and m-RNA levels were quantified using 
the critical threshold (Ct) value. Analysis were 
performed with ABI Prism 7000 (SDS Software). 
Controls without RT and with no template cDNA 
were performed with each assay. To compensate 
for variations in input RNA amounts, and to ma-
ximize efficiency of reverse transcription, GADPH 
mRNA was quantified and results were norma-
lized to these values. Relative gene expression 
levels were obtained using the ∆∆Ct method [20]. 
Amplification-specific transcripts were further 
confirmed by obtaining melting curve profiles. 
Results 
The frequencies of the investigated genotypes 
of locus -463 in the myeloperoxidase-encoding 
gene in the study population are summarized in 
Table 1 and Table 2. The AA genotype at locus 
-463 of the myeloperoxidase-encoding gene has 
a 2.87-fold increased risk of developing COPD 
Table 1.  Frequency of genotypes and alleles at -463 polymorphic site of the MPO-encoding gene in COPD and in subjects 
without COPD. The distribution of genotypes in the group of patients with COPD differs from the distribution in 
healthy subjects (Chi2 = 114.19, p < 0.001)
Allele frequency Genotype distribution
A [%] G [%]  AA [n%] AG [n%] GG [n%]
COPD patients 46 54 45 (25) 77 (41) 64 (34)
Healthy subjects 24 76 22 (10) 40 (18) 158 (72) 
COPD — chronic obstructive pulmonary disease
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Table 2.  Frequency of genotypes and alleles at -129G/A genomic site of the MPO-encoding gene in COPD patients and 
in the healthy group. The distribution of genotypes in the group of patients with COPD does not differ from the 
distribution in healthy subjects (Chi2 = 5.48, p = 0.064)
Allele frequency Genotype distribution
A [%] G [%] AA [n%] AG [n%] GG [n%]
COPD patients 25 75 4 (2) 60 (32) 122 (66) 
Healthy subjects 26 74 6 (3) 69 (31) 145 (66) 
COPD — chronic obstructive pulmonary disease
(95% CI: 1.651–4.997) as compared to AG and GG 
genotypes. Carriage of the AA and AG genotypes 
vs the GG genotype did not significantly affect 
the risk of developing COPD (OR: 0.813, 95% CI: 
0.521–1.270). Carriage of the AA genotype relative 
to the GG genotype increases the risk of COPD in 
smokers (OR: 5050, 95% CI: 2.808–9.080). The 
AG genotype as compared to GG was also found 
to be a risk factor for COPD (OR: 4.752, 95% CI: 
2.941–7.679). Carriage of the AA and AG geno-
type vs. the GG genotype is also a risk factor for 
the development of COPD (OR: 4.857, 95% CI: 
3.187–7.406). In contrast, the AA genotype did 
not increase the risk of developing COPD relative 
to carriage of the AG genotype (OR: 1.0634, 95% 
CI: 0.562–2.001). 
Genotypic distribution of the polymorphic 
locus -129 of the gene encoding MPO was not 
different in healthy subjects and patients and was 
not associated with the risk of developing COPD. 
The myeloperoxidase-encoding gene expres-
sion for the -463AA genotype was significantly 
higher in both healthy subjects and COPD pa-
tients (Table 3). Patients with the AA genotype 
demonstrated a higher gene expression than 
healthy individuals with the AA genotype. The 
gene expression did not differ for the remaining 
genotypes. 
No differences in gene expression were re-
ported for the polymorphic variants of locus -129 
of the myeloperoxidase-encoding gene (Table 4). 
Discussion
The obtained results show the polymorphic 
locus -129 of the gene encoding human myelope-
roxidase is not associated with the risk of develo-
ping COPD. The AA genotype at the polymorphic 
site -463 of the myeloperoxidase-encoding gene 
has a clear association with the occurrence of 
chronic obstructive pulmonary disease. It is also 
associated with an increased expression of mRNA 
of the enzyme-encoding gene and probably with 
the enzyme activity that was not studied in this 
research. As reported in the literature, neutrophil 
granulocytes are the most important cells respon-
sible for the development of COPD [21, 22]. The 
mediators released by neutrophils damage the 
Table 4.  Expression of the myeloperoxidase-encoding 
gene at site -129 according to the genotype in 
patients with COPD and in healthy subjects. The 
gene expression in the serum expressed as 2-DDCt
Genotype Gene expression
COPD patients
AA 0.42 ± 0.12
AG 0.31 ± 0.18
GG 0.30 ± 0.17
Healthy subjects
AA 0.41 ± 0.16
AG 0.29 ± 0.15
GG 0.31 ± 0.16
No inter-group differences in expression were observed. COPD — chronic 
obstructive pulmonary disease
Table 3.  Expression of the myeloperoxidase-encoding 
gene at site -463 according to the genotype in 
patients with COPD and in healthy subjects. The 
gene expression in the serum expressed as 2-DDCt
Genotype Gene expression
COPD patients
AA 0.56 ± 0.12*, #
AG 0.31 ± 0.18
GG 0.29 ± 0.17
Healthy subjects
AA 0.41 ± 0.16**
AG 0.29 ± 0.15
GG 0.25 ± 0.16
*Significantly higher than gene expression for phenotypes AG and GG in pa-
tients, p < 0.01; **significantly higher than gene expression for AG and GG 
phenotypes in healthy subjects, p < 0.01; #Significantly higher in patients with 
AA phenotype than in healthy subjects with AA phenotype. 
COPD — chronic obstructive pulmonary disease
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respiratory epithelium, cause free radical and 
proteolytic tissue damage, and initiate respiratory 
tract remodeling typical of COPD [21, 22]. The 
increased expression of the AA genotype of locus 
-463 in the myeloperoxidase-encoding gene is 
associated in our studies both with an increased 
risk of developing COPD and with an increased 
expression of the enzyme mRNA. It is well known 
that neutrophils are the cells responsible for the 
development of COPD, however, the significance 
of the mediators released by myeloperoxidase is 
controversial. On the one hand, myeloperoxidase 
kills bacteria that cause exacerbations of infection 
in the course of COPD but, on the other hand, it 
damages the tissues of the respiratory tract [1, 2, 
21, 22]. The lack of “tuning” the magnitude of the 
reaction involving the secretion of mediators by 
neutrophils against the infection may be respon-
sible for the remodeling of the respiratory tract 
and the formation of emphysematous bullae [23]. 
Such a situation resembles an excessive immune 
response in autoimmune diseases, but this is only 
our hypothesis. Similarly, peroxidase deficiency 
is associated with a disease similar to chronic 
granulomatous disease and has a predisposition 
to severe Candida albicans infections [24]. It has 
recently been demonstrated that myeloperoxidase 
itself is a mediator of post-ischemic arrhythmo-
genic cardiomyopathy [25]. Conceivably, it is 
either through its own actions, or through the 
peptides resulting from its proteolytic degrada-
tion, a mediator of bronchial remodeling. The 
effects of myeloperoxidase on cardiac vessels 
and on the heart itself suggest that it contributes 
to the development of pulmonary hypertension 
and pulmonary heart disease in COPD, which 
requires further investigation. The role of HClO, 
the main product of myeloperoxidase enzyme 
activity in inducing bronchial remodeling and 
emphysema, cannot be ruled out, although there 
has been no research work on this subject to date. 
Undoubtedly, reactive oxygen species, including 
hypochloride produced by myeloperoxidase, have 
a well-established role as COPD development 
factors [26]. It is interesting what transcription 
factors affect the expression of the myeloperoxi-
dase gene and what their association is with the 
polymorphic sites of the promoter region of the 
gene in question. The polymorphism of locus 
-463 in the myeloperoxidase-encoding gene is 
associated with a risk of developing Alzheimer’s 
disease [27]. On the other hand, studies of Asian 
populations have shown that the AA genotype is 
associated with a reduced risk of lung cancer [28]. 
Also, the GG genotype reduces the risk of deve-
loping type 2 diabetes [29]. Subjects predisposed 
to developing lung cancer in the course of COPD 
may be those who carry the GG genotype. The AA/
GA genotype at locus -463 promote the develop-
ment of hypertension in people with a low BMI 
and without diabetes [30]. It would be interesting 
to check the blood pressure distribution in our 
study group, but this was not the subject of the 
research. The AA/GA variant reduced the risk of 
colorectal cancer in the Chinese population [31]. 
The disadvantage of our research was the 
fact that we did not determine myeloperoxidase 
activity and expression in sputum. This would 
give a more realistic and detailed picture of the 
correlations between the polymorphic variants of 
the myeloperoxidase gene and the enzyme acti-
vity, as well as its expression in the airways. On 
the other hand, COPD is a systemic disease and 
changes in its expression in the blood may have 
some significance in its pathogenesis. The studies 
need to be repeated in larger groups and in other 
populations coming from different regions. In 
addition, it needs to include the gene expression 
in induced sputum, or in bronchoalveolar lavage. 
In our work, we did not analyze the relationships 
between the polymorphic variants and the seve-
rity/risk of COPD. An analysis with division into 
subgroups would have resulted in there being too 
few patients to obtain reliable results. It would be 
interesting to see whether the genotype distribu-
tions in the non-smoking group would be similar 
to the distributions in smokers without COPD. 
Such studies, however, have not been conduc-
ted. That being said, in a study by Kowalski et 
al. concerning the polymorphic variants of the 
myeloperoxidase-encoding gene (the same as in 
our study), distributions of genotypes obtained in 
healthy subjects were similar to those obtained 
in our work for smokers (the control group in our 
study) [14]. The aforementioned study was also 
conducted in the Polish population. It indicates 
that the studied gene variants are unlikely to be 
associated with the risk of nicotine dependence 
syndrome. The distribution, which is similar to 
ours, supports the probable repeatability of the 
results we obtained. The contribution of genetic 
factors to the pathogenesis of nicotine addiction 
is likely to be low and involves only the genes 
coding for cytochrome C450 variants and receptor 
proteins in the central nervous system [32]. 
Conclusions
1.  The polymorphism of locus -463 in the my-
eloperoxidase-encoding gene is associated 
Andrzej Witusik et al., Myeloperoxidase gene polymorphism in COPD
121www.journals.viamedica.pl
with the risk of developing COPD. Carriage 
of the AA genotype is associated with a 2.87-
fold higher risk of COPD. Also, the myelop-
eroxidase gene expression in the blood is 
higher in subjects with the AA genotype, both 
healthy and sick; however, it is significantly 
higher in the patient group than in healthy 
subjects 
2.  The polymorphism of locus -129 in the my-
eloperoxidase-encoding gene has no associ-
ation with the risk of COPD. 
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